
Nannan Thirumavalavan, MD, reflects on how the FDA’s testosterone labeling changes, informed by the TRAVERSE trial, have influenced TRT prescribing and clinician confidence over the past year.

Nannan Thirumavalavan, MD, reflects on how the FDA’s testosterone labeling changes, informed by the TRAVERSE trial, have influenced TRT prescribing and clinician confidence over the past year.